J., Prendergast, G., Howe, S
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
The study was partially funded by the maker of the supplement (Juvenon Cellular Health Supplement, Juvenon Inc.) [7][22]
Furthermore, spectrophotometric measurements can be influenced by compounds such as carotenoids, which absorb at similar wavelengths to DPPH, or by sample turbidity
Antioxidants help reduce oxidative stress by preventing ROS formation, blocking ROS from causing cellular damage, and repairing any damage that occurs
